Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Subviral Agents

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Anchoring ALS Prognosis: Neurofilament Light Chain Outperforms Inflammatory, Metabolic, and CNS Barrier Biomarkers in the METABALS Cohort.

Molecular neurobiology·2026

Same author

Improving ALS Molecular Diagnosis Through Functional Assays: Reassessment of a <i>SOD1</i> Variant of Uncertain Significance.

International journal of molecular sciences·2025

Same author

A Sensitive and Versatile Cell-Based Assay Combines Luminescence and Trapping Approaches to Monitor Unconventional Protein Secretion.

Traffic (Copenhagen, Denmark)·2025

Same author

Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.

Lancet (London, England)·2025

Same author

High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial.

JAMA·2025

Same author

Comparative Performances of 4 Serum NfL Assays, pTau181, and GFAP in Patients With Amyotrophic Lateral Sclerosis.

Neurology·2025

Search research articles

Related Experiment Video

Updated: Sep 5, 2025

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans

Published on: January 8, 2015

Prionoids in amyotrophic lateral sclerosis.

Philippe Gosset¹, William Camu¹, Cedric Raoul¹

¹INM, Univ Montpellier, INSERM, CNRS, Montpellier 34095, France.

Brain Communications

|July 5, 2022

Summary

This summary is machine-generated.

Amyotrophic lateral sclerosis (ALS) involves motoneuron loss and spreads like prions. Key proteins like SOD1, TDP-43, and FUS may act as prionoids, driving ALS pathology progression.

Keywords:

amyotrophic lateral sclerosis physiopathology prion-like protein aggregation therapy

More Related Videos

Monitoring Cell-to-cell Transmission of Prion-like Protein Aggregates in Drosophila Melanogaster

Monitoring Cell-to-cell Transmission of Prion-like Protein Aggregates in Drosophila Melanogaster

Published on: March 12, 2018

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models

Published on: March 24, 2019

Related Experiment Videos

Last Updated: Sep 5, 2025

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans

Published on: January 8, 2015

Monitoring Cell-to-cell Transmission of Prion-like Protein Aggregates in Drosophila Melanogaster

Monitoring Cell-to-cell Transmission of Prion-like Protein Aggregates in Drosophila Melanogaster

Published on: March 12, 2018

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models

Published on: March 24, 2019

Area of Science:

Neuroscience
Molecular Biology
Genetics

Background:

Amyotrophic lateral sclerosis (ALS) is the third most common neurodegenerative disease.
It involves progressive loss of motor neurons in the central nervous system.
ALS symptoms include muscle weakness, wasting, and paralysis, typically starting in midlife.

Purpose of the Study:

To review the molecular and cellular mechanisms of prionoid propagation in ALS.
To discuss the role of specific proteins in ALS pathology spread.
To explore the similarities between ALS and prion diseases.

Main Methods:

Literature review focusing on recent research in ALS.
Analysis of molecular and cellular mechanisms of protein aggregation and spread.
Comparison of ALS pathology with prion disease mechanisms.

Main Results:

ALS pathology spreads progressively along neuroanatomical tracts, suggesting prionoid involvement.
Key ALS-associated proteins, including SOD1, TDP-43, and FUS, are implicated as potential prionoids.
These proteins may contribute to the characteristic pathology and spread observed in ALS patients.

Conclusions:

Prionoid propagation is a significant factor in ALS pathogenesis.
Understanding these mechanisms is crucial for developing effective ALS therapies.
Further research into SOD1, TDP-43, and FUS as prionoids is warranted.